Available through:
EDTA Chelation
Available Dosage Strengths
EDTA, Vitamin C, B-Complex, Procaine, Magnesium
Product Overview
EDTA combined with Procaine, vitamins (C, B-complex), magnesium, and trace minerals intended for heavy-metal chelation under medical supervision.
Benefits
- Chelates certain metals (lead, cadmium; limited evidence for others)
- Supports antioxidant pathways
Mechanism of Action (MOA)
- EDTA: binds divalent and trivalent metals for renal excretion.
- Vitamin C +: Provides antioxidant support during chelation.
- Procaine: Known for its chelating properties, aids in the removal of heavy metals from tissues and organs, supporting overall detoxification.
Side Effects
- Low calcium levels (EDTA)
- Kidney strain
- Nausea, hypotension
- Nephrotoxicity: Edetate CALCIUM disodium is potentially nephrotoxic. Renal tubular acidosis and fatal nephrosis may occur.
Contraindications
These intravenous infusions should not be administered to patients with:
- Chronic renal insufficiency
- Congestive heart failure
- Atrial fibrillation, and known allergies on vitamins, minerals, and related substances. and other ingredients contained in the IV infusion bag.
- This should not be administered to patients below 18 years old.
- EDTA is contradicted for those who have active renal disease or anuria; hepatitis.
- Pregnancy & breastfeeding.
- Kidney disease
- Hypocalcemia
Interactions
- Increased renal clearance of some metals and minerals
- Drug Interactions: Digoxin, diuretics, potassium-depleting medicines. If the patient is taking any medicine, check first for any possible drug interaction before use. Do not take alcohol, sleep aids, or tranquilizers of other CNS depressants.
- EDTA x Chloramphenicol (Systemic): Myelosuppressive Agents may enhance the myelosuppressive effect of Chloramphenicol (Systemic).
- EDTA x Cladribine: May enhance the myelosuppressive effect of Myelosuppressive Agents.
- EDTA x Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased.
- EDTA x BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical).
References (General Scientific Sources)
These are general categories of references typically supporting nutrient-based IV therapy mechanisms:
- Modern Nutrition in Health and Disease, 12th Ed.
- NIH Office of Dietary Supplements – Fact Sheets (Vitamin C, B12, Magnesium, Zinc, etc.)
- European Food Safety Authority (EFSA) scientific opinions on micronutrients
- PubMed-indexed reviews on IV vitamin therapy, antioxidant therapy, NAC, glutathione, and EDTA chelation
- Drug–nutrient interaction data from Lexicomp & Micromedex